Rapid testing solutions to get back to business
Implementing simple safety measures can help reduce risks of spreading COVID-19 as businesses and employers resume operations, client meetings, corporate travel, and more. COVID-19 safety measures can include physical distancing, masking, handwashing, and testing. Developing a testing plan can allow you the flexibility to scale up or down as guidelines or trends in COVID-19 infections evolve.
Some benefits of testing include:
- Reduce risk of spreading COVID-19 in the workplace
- Enhance employee confidence in safety protocols
- Minimize cancellation of business or client meetings due to COVID-19
- Lessen productivity losses from staff shortages, outbreaks, or shutdowns
- Limit disruptions to business operations
- Compliance with evolving local and state regulated guidelines and protocols
Refer to CDC Guidelines for the most current local guidance.
A path forward to bring people back together safely
As a leading single source-supplier of COVID-19 testing worldwide, we can partner with your organization to curate and implement a solution that provides simplicity and convenience at every step. Our team can offer support for in-house testing or connect you with a full-service testing provider. Unlike some providers, there’s no need to commit to long-term contracts, giving you the flexibility to test on your terms.
3 simple steps to help make your meetings safer
Just tell us about your company or event, and we will help you choose a testing solution that fits your needs and budget
We aim to simplify and streamline your testing and reporting so your workforce can remain healthy and productive
We optimize your testing program to meet your evolving needs, helping to ensure that they are scalable, cost-efficient and most importantly, effective
Frequently asked questions
NOTE: Testing for the Accula SARS-CoV-2 Test is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high, moderate, or waived complexity tests. The Accula SARS-CoV-2 Test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This test has not been FDA cleared or approved but has been authorized for emergency use by the FDA for use by laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. §263a, that meet requirements to perform high, moderate, or waived complexity tests. The test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
For Emergency Use Authorization (EUA) Only. For prescription use only. For in vitro diagnostic use.